Superiority of infectivity-based over particle-based methods for quantitation of drug resistant HIV-1 as inocula for cell cultures

Journal of Virological Methods

Volumn 141, Issue 1, 2007, Pages 87-96

  Tschochner, Monika ^a   Schwingel, Eva ^a   Thein, Christine ^a   Wittmann, Sabine ^a   Paatz, Christiane ^a   Walter, Hauke ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Drug resistance; HIV; Infectivity; Subtype; Viral quantitation

Indexed keywords

ANTIGEN P24; BETA GALACTOSIDASE; GENOMIC RNA; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ANTIBIOTIC RESISTANCE; ARTICLE; CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TITRATION;

ANTI-HIV AGENTS; BETA-GALACTOSIDASE; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; EVALUATION STUDIES; GENES, REPORTER; GENOME, VIRAL; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; LUCIFERASES; LUMINESCENT MEASUREMENTS; RNA, VIRAL;

CERCOPITHECINE HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33847070059     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2006.11.040     Document Type: Article

References (47)

1. Antunes R., Figueiredo S., Bartolo I., Pinheiro M., Rosado L., Soares I., Lourenco H., and Taveira N. Evaluation of the clinical sensitivities of three viral load assays with plasma samples from a pediatric population predominantly infected with human immunodeficiency virus type 1 subtype G and BG recombinant forms. J. Clin. Microbiol. 41 (2003) 3361-3367
2. Ball S.C., Abraha A., Collins K.R., Marozsan A.J., Baird H., Quinones-Mateu M.E., Penn-Nicholson A., Murray M., Richard N., Lobritz M., Zimmerman P.A., Kawamura T., Blauvelt A., and Arts E.J. Comparing the ex vivo fitness of CCR5-tropic human immunodeficiency virus type 1 isolates of subtypes B and C. J. Virol. 77 (2003) 1021-1038
3. Beerenwinkel N., Daumer M., Oette M., Korn K., Hoffmann D., Kaiser R., Lengauer T., Selbig J., and Walter H. Geno2pheno: estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res. 31 (2003) 3850-3855
4. Berkhout B., Back N.K., de Ronde A., Jurriaans S., Bakker M., Parkin N.T., and van der H.L. Identification of alternative amino acid substitutions in drug-resistant variants of the HIV-1 reverse transcriptase. AIDS 20 (2006) 1515-1520
5. Bleiber G., Munoz M., Ciuffi A., Meylan P., and Telenti A. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J. Virol. 75 (2001) 3291-3300
6. Bourinbaiar A.S. The ratio of defective HIV-1 particles to replication-competent infectious virions. Acta Virol. 38 (1994) 59-61
7. Brenner B.G., Turner D., and Wainberg M.A. HIV-1 drug resistance: can we overcome?. Expert Opin. Biol. Ther. 2 (2002) 751-761
8. Buonaguro L., Tagliamonte M., Tornesello M.L., Pilotti E., Casoli C., Lazzarin A., Tambussi G., Ciccozzi M., Rezza G., and Buonaguro F.M. Screening of HIV-1 isolates by reverse heteroduplex mobility assay and identification of non-B subtypes in Italy. J. Acquir. Immune Defic. Syndr. 37 (2004) 1295-1306
9. Campbell T.B., Schneider K., Wrin T., Petropoulos C.J., and Connick E. Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J. Virol. 77 (2003) 12105-12112
10. Coombs R.W., Henrard D.R., Mehaffey W.F., Gibson J., Eggert E., Quinn T.C., and Phillips J. Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction. J. Clin. Microbiol. 31 (1993) 1980-1986
11. Corrigan G.E., Al Khalili L., Malmsten A., Thorstensson R., Fenyo E.M., Kallander C.F., and Gronowitz J.S. Differences in reverse transcriptase activity versus p24 antigen detection in cell culture, when comparing a homogeneous group of HIV type 1 subtype B viruses with a heterogeneous group of divergent strains. AIDS Res. Hum. Retroviruses 14 (1998) 347-352
12. De la Carriere L.C., Paulous S., Clavel F., and Mammano F. Effects of human immunodeficiency virus type 1 resistance to protease inhibitors on reverse transcriptase processing, activity, and drug sensitivity. J. Virol. 73 (1999) 3455-3459
13. Deeks S.G. Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet 362 (2003) 2002-2011
14. Ekstrand D.H., Awad R.J., Kallander C.F., and Gronowitz J.S. A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier-bound template and non-radioactive-product detection, with special reference to human-immunodeficiency-virus isolation. Biotechnol. Appl. Biochem. 23 (1996) 95-105
15. Fransen K., Beelaert G., and Van der G.G. Evaluation of four HIV antigen tests. J. Virol. Methods 93 (2001) 189-193
16. Fu W., Dang Q., Nagashima K., Freed E.O., Pathak V.K., and Hu W.S. Effects of Gag mutation and processing on retroviral dimeric RNA maturation. J. Virol. 80 (2006) 1242-1249
17. Gallego O., Ruiz L., Vallejo A., Clotet B., Leal M., and Soriano V. Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain. J. Clin. Microbiol. 40 (2002) 3865-3866
18. Gomes P., Palma A.C., Cabanas J., Abecasis A., Carvalho A.P., Ziermann R., Diogo I., Goncalves F., Lobo C.S., and Camacho R. Comparison of the COBAS TAQMANtrade mark HIV-1 HPS with VERSANT HIV-1 RNA 3.0 Assay (bDNA) for plasma RNA quantitation in different HIV-1 subtypes. J. Virol. Methods 135 (2006) 223-228
19. Heneine W., Yamamoto S., Switzer W.M., Spira T.J., and Folks T.M. Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1. J. Infect. Dis. 171 (1995) 1210-1216
20. Holguin A., Alvarez A., and Soriano V. Heterogeneous nature of HIV-1 recombinants spreading in Spain. J. Med. Virol. 75 (2005) 374-380
21. Isel C., Ehresmann C., Walter P., Ehresmann B., and Marquet R. The emergence of different resistance mechanisms toward nucleoside inhibitors is explained by the properties of the wild type HIV-1 reverse transcriptase. J. Biol. Chem. 276 52 (2001) 48725-48732 Epub 2001 Oct 19
22. Johnson V.A., Brun-Vezinet F., Clotet B., Kuritzkes D.R., Pillay D., Schapiro A., and Richman D.D. Update of the drug resistance mutations in HIV-1: fall 2006. Top. HIV Med. 14 (2006) 125-130
23. Johnson V., and Byington R.E. In: Aldovini A., and Walker B.D. (Eds). Quantitative Assays For Virus Infectivity (1990), Stockton Press, New York 71-76
24. Kimpton J., and Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J. Virol. 66 (1992) 2232-2239
25. Krebs R., Immendorfer U., Thrall S.H., Wohrl B.M., and Goody R.S. Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry 36 33 (1997) 10292-10300
26. Maeda Y., Venzon D.J., and Mitsuya H. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177 (1998) 1207-1213
27. Mammano F., Petit C., and Clavel F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J. Virol. 72 (1998) 7632-7637
28. Marozsan A.J., Fraundorf E., Abraha A., Baird H., Moore D., Troyer R., Nankja I., and Arts E.J. Relationships between infectious titer, capsid protein levels, and reverse transcriptase activities of diverse human immunodeficiency virus type 1 isolates. J. Virol. 78 (2004) 11130-11141
29. Means R.E., Greenough T., and Desrosiers R.C. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus. J. Virol. 71 (1997) 7895-7902
30. Michael N.L., Herman S.A., Kwok S., Dreyer K., Wang J., Christopherson C., Spadoro J.P., Young K.K., Polonis V., McCutchan F.E., Carr J., Mascola J.R., Jagodzinski L.L., and Robb M.L. Development of calibrated viral load standards for group M subtypes of human immunodeficiency virus type 1 and performance of an improved AMPLICOR HIV-1 MONITOR test with isolates of diverse subtypes. J. Clin. Microbiol. 37 (1999) 2557-2563
31. Nadal D., Boni J., Kind C., Varnier O.E., Steiner F., Tomasik Z., and Schupbach J. Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric human immunodeficiency virus type 1 infection. J. Infect. Dis. 180 (1999) 1089-1095
32. Naeger L.K., Margot N.A., and Miller M.D. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: analysis of enzyme processivity, chain-terminator removal and viral replication. Antivir. Ther. 6 (2001) 115-126
33. Nijhuis M., Schuurman R., de Jong D., Erickson J., Gustchina E., Albert J., Schipper P., Gulnik S., and Boucher C.A. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13 (1999) 2349-2359
34. Quinones-Mateu M.E., and Arts E.J. Fitness of drug resistant HIV-1: methodology and clinical implications. Drug Resist. Updat. 5 (2002) 224-233
35. Reed L.J., and Muench H. A simple method of estimating fifty percent endpoints. Am Hyg 27 (1938) 493-497
36. Reicin A.S., Paik S., Berkowitz R.D., Luban J., Lowy I., and Goff S.P. Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity. J. Virol. 69 (1995) 642-650
37. Richman D.D., Morton S.C., Wrin T., Hellmann N., Berry S., Shapiro M.F., and Bozzette S.A. The prevalence of antiretroviral drug resistance in the United States. AIDS 18 (2004) 1393-1401
38. Schmidt B., Walter H., Moschik B., Paatz C., Van Vaerenbergh K., Vandamme A.M., Schmitt M., Harrer T., Uberla K., and Korn K. Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS. 14 (2000) 1731-1738
39. Stevens G., Rekhviashvili N., Scott L.E., Gonin R., and Stevens W. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J. Clin. Microbiol. 43 (2005) 857-861
40. Telenti A., Martinez R., Munoz M., Bleiber G., Greub G., Sanglard D., and Peters S. Analysis of natural variants of the human immunodeficiency virus type 1 gag-pol frameshift stem-loop structure. J. Virol. 76 (2002) 7868-7873
41. Von Truchsess I., Harris B., Schatzl H.M., and Hackett Jr. J. The first B/G intersubtype recombinant form of human immunodeficiency virus type 1 (HIV-1) identified in Germany was undetected or underquantitated by some commercial viral load assays. J. Med. Virol. 78 (2006) 311-317. http://www.genafor.org/ URL: http://www.genafor.org/
42. Walter H., Low P., Harrer T., Schmitt M., Schwingel E., Tschochner M., Helm M., Korn K., Uberla K., and Schmidt B. No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual. J. Acquir. Immune Defic. Syndr. 31 (2002) 137-146
43. Walter H., Schmidt B., Korn K., Vandamme A.M., Harrer T., and Uberla K. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J. Clin. Virol. 13 (1999) 71-80
44. Wang C.T., and Barklis E. Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants. J. Virol. 67 (1993) 4264-4273
45. Wiegers K., Rutter G., Kottler H., Tessmer U., Hohenberg H., and Krausslich H.G. Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J. Virol. 72 (1998) 2846-2854
46. Wu S.C., Spouge J.L., Merges M.J., Conley S.R., and Nara P.L. A cytopathic infectivity assay of human immunodeficiency virus type 1 in human primary macrophages. J. Virol. Methods 59 (1996) 45-55
47. Zennou V., Mammano F., Paulous S., Mathez D., and Clavel F. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72 (1998) 3300-3306